Product Name:methyl 3-iodo-4-methylbenzoate

IUPAC Name:methyl 3-iodo-4-methylbenzoate

CAS:90347-66-3
Molecular Formula:C9H9IO2
Purity:95%
Catalog Number:CM101804
Molecular Weight:276.07

Packing Unit Available Stock Price($) Quantity
CM101804-100g in stock ǟǎ
CM101804-500g in stock ţǟţ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:90347-66-3
Molecular Formula:C9H9IO2
Melting Point:-
Smiles Code:O=C(OC)C1=CC=C(C)C(I)=C1
Density:1.666g/cm3
Catalog Number:CM101804
Molecular Weight:276.07
Boiling Point:302.9°C at 760 mmHg
MDL No:MFCD00230583
Storage:Store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Carbonyl Compounds
In organic chemistry, a carbonyl group is a functional group with the formula C=O, composed of a carbon atom double-bonded to an oxygen atom, and it is divalent at the C atom. It is common to several classes of organic compounds (such as aldehydes, ketones and carboxylic acids), as part of many larger functional groups. A compound containing a carbonyl group is often referred to as a carbonyl compound.
Olverembatinib
Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs. 

Related Products